Asterias Biotherapeutics (AST) Reports Positive Outcome from Safety Review Committee for AST-VAC2
Tweet Send to a Friend
Asterias Biotherapeutics, Inc. (NYSE: AST) today announced that the Safety Review Committee (SRC) for the first clinical trial of AST-VAC2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
